We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Diabetes & Endocrinology

Enhanced Glycaemic Control in Type 2 Diabetes: Digital Therapeutics Combined with CGM Show Superior Outcomes

MedXY Editorial Team•Oct 3, 2026•Diabetes & Endocrinology
continuous glucose monitoringdigital therapeuticsglycaemic controltype 2 diabetes

Highlight

  • Combination of the digital therapeutic glucura with intermittent continuous glucose monitoring (CGM) significantly improved HbA1c reduction compared to CGM with standard care alone in non-insulin-treated type 2 diabetes.
  • Glucura users achieved higher rates of stringent glycaemic targets (HbA1c <7.0% and <6.5%) and experienced greater weight loss.
  • Beyond metabolic benefits, glucura improved mental health and reduced diabetes-related distress without serious adverse events.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Dynamic Patterns of Body Composition Remodeling Around Type 2 Diabetes Diagnosis: Insights from Three European and US CohortsThis study reveals distinctive trajectories of BMI, body roundness, and muscle strength surrounding type 2 diabetes diagnosis, highlighting complex body composition changes including pre-diagnosis weight peaks, persistent visceral fat, and Oct 5, 2026Functional Hypothalamic Amenorrhea Phenotype and Cardiovascular Disease RiskFunctional hypothalamic amenorrhea (FHA) in mid-adulthood is linked to increased coronary heart disease risk and type 2 diabetes, independent of traditional factors, highlighting menstrual irregularities as early cardiometabolic risk indicaOct 5, 2026Enhanced Glycaemic Control in Type 2 Diabetes: Digital Therapeutic Glucura Combined with CGM Shows Superior 6-Month OutcomesA randomized trial demonstrates that adding the digital therapeutic glucura to intermittent CGM and standard care significantly improves HbA1c, weight loss, and mental health in non-insulin-treated type 2 diabetes patients over six months.Oct 5, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing &amp; care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Head-to-Head Comparison of Empagliflozin and Dapagliflozin on Liver Outcomes in Type 2 Diabetes with MASLD
A large Korean cohort study found similar hepatic benefits between empagliflozin and dapagliflozin in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease, with no difference in risk of severe liver com
Oct 3, 2026
Unveiling Cardiovascular Benefits of Tirzepatide: Insights from SURPASS-CVOT Using Imputed Placebo Analysis of REWINDAn indirect comparison shows tirzepatide significantly reduces major adverse cardiovascular events and mortality in type 2 diabetes patients, highlighting its potential for improving cardiovascular outcomes.Oct 3, 2026
Early Pregnancy Glycemic Testing Enhances Gestational Diabetes Prediction: Insights from the GO MOMs StudyIn early pregnancy, adding oral glucose tolerance testing or continuous glucose monitoring to clinical factors improves prediction of gestational diabetes mellitus but not large-for-gestational-age births.Oct 3, 2026